Biolegend, 102132, Ultra-LEAF™ Purified anti-mouse CD28 Antibody, 100mg

CD28 is a 44 kD glycoprotein, also known as Tp44 or T44. It is a member of the Ig superfamily, expressed on thymocytes, most peripheral T cells, and NK cells. In association with CD80 (B7-1) and CD86 (B7-2), CD28 acts as the second signal for T and NK cell activation and proliferation. The 37.51 antibody has been reported to augment in vitro T cell proliferation and cytokine production, and promote CTL development.
100mg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Syrian Hamster
Immunogen: C57BL/6 mouse T-cell lymphoma EL-4
Formulation: 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Endotoxin Level: Less than 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.
Preparation: The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration: The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application: FC - Quality testedIP, IHC-F, Costim, Block - Reported in the literature, not verified in house
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per million cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: Additional reported applications (for the relevant formats) include: immunoprecipitation1, in vitro costimulation of T and NK cells1, in vitro blocking of allogeneic mixed leukocyte response and inhibition of MHC-unrestricted CTL cytotoxicity3,4, in vitro induction of thymocyte differentiation2,5-9,11, and immunohistochemical staining of acetone-fixed frozen sections. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) (Cat. No. 102116).
Additional Product Notes: Get a 50% discount on this product when purchased in our Activation Bundles. Restrictions apply. Learn more…
Application References(PubMed link indicates BioLegend citation): Gross JA, et al. 1992. J. Immunol. 149:380. (IP, Costim) Cibotti R, et al. 1997. Immunity 6:245. (Costim) Masten BJ, et al. 1997. Am. J. Respir. Cell Mol. Biol. 16:335. (Block) Nishio M, et al. 1996. J. Immunol. 157:4347. (Block) Zhang N and He Y-W, 2005. J. Exp. Med. 202:395. (Costim) Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Costim) Perchonock CE, et al. 2006. Mol Cell Biol. 26(16):6005. (Costim) Wang W, et al. 2007. J. Immunol. 178:4885. (Costim) Pua HH, et al. 2007. J. Exp. Med. 204:25. (Costim) Perchonock CE, et al. 2007. J. Immunol. 179:1768. Barbi J, et al. 2007. Blood 110:2215. Milpied P, et al. 2011. Blood 118:2993. PubMed Cunningham NR, et al. 2011. Int Immunol. 23:693. PubMed Crispin JC, et al. 2012. J. Immunol. 188:3567. PubMed Li CR, et al. 2014. J Immunol. 192:1425. PubMed Blankenhaus B, et al. 2014. PLoS Pathog. 10:1003913. PubMed
Product Citations: Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed Liu T, et al. 2023. Cardiovasc Res. 119:1046. PubMed Mirji G, et al. 2022. Sci Immunol. 7:eabn0704. PubMed Aso K, et al. 2023. Nat Commun. 14:984. PubMed Li X, et al. 2023. J Clin Invest. 133:. PubMed Mammadli M, et al. 2023. Int J Mol Sci. 24:. PubMed Mabire M, et al. 2023. Nat Commun. 14:1830. PubMed Xiao X, et al. 2023. Nat Commun. 14:2859. PubMed Vereertbrugghen A, et al. 2023. J Neuroinflammation. 20:120. PubMed Wang T, et al. 2023. Commun Biol. 6:613. PubMed Yao RQ, et al. 2023. Mil Med Res. 10:27. PubMed Mammadli M, et al. 2021. Clin Transl Med. 11:e625. PubMed Jairaman A, et al. 2021. Bio Protoc. 11:e4170. PubMed Li H, et al. 2022. Cancer Cell. 40:36. PubMed Kwon H, et al. 2022. Sci Immunol. 7:eabq2630. PubMed Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed Krishnamurty AT, et al. 2022. Nature. 611:148. PubMed Klaus T, et al. 2022. JCI Insight. 7: . PubMed Zhang H, et al. 2022. J Clin Invest. 132: . PubMed Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed Wang Z, et al. 2022. Cell Rep. 41:111890. PubMed Jiang YP, et al. 2022. Int J Mol Sci. 24: . PubMed Jiang X, et al. 2023. Cell Discov. 9:7. PubMed Pitmon E, et al. 2023. PLoS One. 18:e0280916. PubMed Hajjar S, et al. 2022. Cell Death Differ. 29:585. PubMed Ye L, et al. 2022. Cell Metab. 34:595. PubMed Jiang C, et al. 2020. Int J Biol Sci. 2.802083333. PubMed Denk D, et al. 2022. Immunity. 55:2059. PubMed Li X, et al. 2022. Nat Commun. 13:2794. PubMed Qi Z, et al. 2022. Nat Commun. 13:182. PubMed Otano I, et al. 2021. Nat Commun. 12:7296. PubMed Bromley SK, et al. 2020. Cell Reports. 32(9):108085. PubMed Gkountidi AO, et al. 2021. Cancer Immunol Res. 9:748. PubMed Zhao X, et al. 2021. Int J Oral Sci. 13:31. PubMed Byun JK, et al. 2020. Molecular Cell. 80(4):592-606.e8. PubMed Krone A, et al. 2022. Sci Rep. 218:. PubMed Menzel L, et al. 2021. Cell Rep. 37:109878. PubMed Saito S, et al. 2020. Nutrients. 12:. PubMed Liu W, et al. 2021. Stem Cell Res Ther. 12:153. PubMed Potluri HK, et al. 2022. J Immunother Cancer. 10:. PubMed Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed Yi M, et al. 2021. J Hematol Oncol. 14:27. PubMed Zhang C, et al. 2020. Cell Metabolism. 31(1):148-161.e5.. PubMed Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed Hoover DB, et al. 2020. Int Immunopharmacol. 106359:81. PubMed Sekiya T et al. 2018. Cell reports. 24(6):1627-1638 . PubMed Pfenninger P, et al. 2022. Front Immunol. 13:777113. PubMed Stump CT, et al. 2021. Open Biol. 11:210245. PubMed Mammadli M, et al. 2021. Cancers (Basel). 13:. PubMed Du Y, et al. 2022. Nat Commun. 13:231. PubMed Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed Gudgeon N, et al. 2022. Cell Rep. 40:111193. PubMed Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed Yuan Y, et al. 2022. Cell Rep. 38:110256. PubMed Herrera FG, et al. 2021. Cancer Discov. Online ahead of print. PubMed James OJ, et al. 2021. Nat Commun. 12:4290. PubMed Saragovi A, et al. 2020. Elife. 9:00. PubMed Wu J et al. 2019. Immunity. 50(5):1218-1231 . PubMed Kanno T, et al. 2022. Front Immunol. 13:904875. PubMed Han K, et al. 2021. Nat Metab. 3:318. PubMed Frost JN, et al. 2021. Med (N Y). 2:164. PubMed Peng L, et al. 2022. Cell Rep Med. 3:100634. PubMed Becker W, et al. 2021. J Crohns Colitis. 15:1032. PubMed Ohtsuka J, et al. 2021. iScience. Online ahead of print. PubMed Daneshmandi S, et al. 2021. Elife. 10:. PubMed Liu J, et al. 2020. Nat Commun. 11:6396. PubMed Ma X, et al. 2020. Immunity. 53:1315. PubMed Watson MJ, et al. 2021. Nature. 591:645. PubMed Zhai X, et al. 2021. Sci Adv. 7:eabk0490. PubMed Zhang R, et al. 2022. Front Pharmacol. 13:870848. PubMed He Y, et al. 2019. JCI Insight. 4:e130416. PubMed Yuan X, et al. 2017. Elife. 6:e29540. PubMed Ye Q, et al. 2022. NPJ Vaccines. 7:84. PubMed Teh MR, et al. 2021. Front Immunol. 12:714613. PubMed Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed Woo MS, et al. 2021. J Exp Med. :218. PubMed Minns D, et al. 2021. Nat Commun. 12:1285. PubMed Wang D, et al. 2022. EMBO Rep. 23:e53691. PubMed Koch K, et al. 2022. Int J Mol Sci. 23:. PubMed Xu Y, et al. 2021. iScience. 24:103445. PubMed Sobecki M, et al. 2022. Cell Stem Cell. 29:1459. PubMed Kumar V, et al. 2022. JACC Basic Transl Sci. 7:1038. PubMed Xu L, et al. 2022. Nat Commun. 13:6881. PubMed Luo ZW, et al. 2021. Int J Nanomedicine. 16:2949. PubMed Zhang Z, et al. 2021. Front Immunol. 12:699478. PubMed Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed Guo Z, et al. 2022. Neurobiol Pain. 12:100096. PubMed Okubo A, et al. 2021. Int J Mol Sci. 23:. PubMed Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
RRID: AB_11150408 (BioLegend Cat. No. 102115) AB_11147170 (BioLegend Cat. No. 102116) AB_2810330 (BioLegend Cat. No. 102121) AB_2810331 (BioLegend Cat. No. 102122) AB_2810332 (BioLegend Cat. No. 102131) AB_2810333 (BioLegend Cat. No. 102132)
Disclaimer: This product may be used for research purposes only. It is not licensed for resale and may only be used by the buyer. This product may not be used and is not licensed for clinical assays where the results of such assays are provided as a diagnostic service. If a diagnostic or therapeutic use is anticipated then a license must be requested from the University of California. The availability of such diagnostic and therapeutic use license(s) cannot be guaranteed from the University of California.
Structure: Ig superfamily, 44 kD
Distribution: Thymocytes, CD4+, CD8+ peripheral T cells, NK cells
Function: Costimulates T and NK cells
Ligand/Receptor: CD80 (B7-1), CD86 (B7-2)
Cell Type: NK cells, T cells, Thymocytes, Tregs
Biology Area: Costimulatory Molecules, Immunology
Molecular Family: CD Molecules
Antigen References: 1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Lenschow DJ, et al. 1996. Annu. Rev. Immunol. 14:233. 3. Gross JA, et al. 1992. J. Immunol. 149:380.
Gene ID: 12487
UniProt: View information about CD28 on UniProt.org
Clone: 37.51
Regulatory Status: RUO
Other Names: Tp44, T44
Isotype: Syrian Hamster IgG
Q: Do you guarantee that your antibodies are totally pathogen free?
A: BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.
Q: Does BioLegend test each Ultra-LEAF™ antibody by functional assay?
A: No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.
Q: Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?
A: No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.
Q: Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?
A: We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.